A decrease in sensory nerve action potentials (SNAP) amplitude has been recently reported in some patients during the course of multifocal motor neuropathy with conduction blocks (MMNCB). It is not known if those patients have different clinical expression and disability when compared with typical MMNCB. Clinical, biological and electrophysiological assessments were performed in 15 patients fitting the diagnosis criteria of MMNCB, including normal SNAP amplitude at initial examination. Patients presenting with nerve entrapment or associated disease causative of sensory neuropathy were excluded. Median time of follow-up was 3 years (1–17 years). At the last examination, four patients had at least one SNAP amplitude below 50% of normal value. None had clinically objective sensory loss. Clinical and electrophysiological data obtained at the last examination were compared between patients with normal SNAP amplitude and patients with decreased SNAP amplitude. No difference between both population in term of age, sex, disease duration, anti-GM1 antibody titers, CSF data and number of conduction blocks was noted. In contrast, patients with decreased SNAP amplitude had worse overall neuropathy limitation scale (ONLS) scores (7 vs. 2; p = 0.02), a higher number of affected nerves (12.5 vs. 4; p = 0.018), a higher number of affected limb regions (6 vs. 2; p = 0.019) and lower median CMAP amplitude (2 mV vs. 6.5 mV; p = 0.04). They were all dependent on higher doses of IVIg (1.4 g/(kg 4 weeks vs. 0.6; p = 0.018). A reduction in SNAP amplitude during the course of MMNCB is associated with a more severe disease and a more prominent axonal loss. This result needs to be confirmed in a larger cohort.
Multifocal motor neuropathy with conduction block Axonal degeneration Lewis–Sumner syndrome Sensory nerve action potentials Intravenous immunoglobulin
This is a preview of subscription content, log in to check access.
We thank Pr Said Beydoun for revision of the manuscript.
Azulay JP, Blin O, Boucraut J, Pouget J, Serratrice G (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double blind placebo controlled trial. Neurology 44:429–432PubMedGoogle Scholar
Bouche P, Moulonguet A, Younes-Chennoufi AB et al (1995) Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 59(1):38–44CrossRefPubMedGoogle Scholar
Corse AM, Chaudhry V, Crawford TO, Cornblath DR, Kuncl RW, Griffin JW (1996) Sensory nerve pathology in multifocal motor neuropathy. Ann Neurol 39(3):319–325CrossRefPubMedGoogle Scholar
Delmont E, Azulay JP, Giorgi R, Attarian S, Verschueren A, Uzenot D, Pouget J (2006) Multifocal motor neuropathy with and without conduction block, a single entity? Neurology 67:592–596CrossRefPubMedGoogle Scholar
European federation of neurological societies/peripheral nerve society guideline on management of multifocal motor neuropathy (2006) Eur J Neurol 13:802–80Google Scholar
Graham RC, Hughes RA (2006) A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 77:973–976CrossRefPubMedGoogle Scholar
Krarup C, Stewart JD, Sumner AJ, Pestronk A, Lipton SA (1990) A syndrome of asymmetric limb weakness with motor conduction block. Neurology 40(1):118–127PubMedGoogle Scholar
Lambrecq V, Krim E, Rouanet-Larriviere M, Lagueny A (2009) Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study. Muscle Nerve 2:131–136CrossRefGoogle Scholar
Leger JM (1995) Multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 8:359–363PubMedCrossRefGoogle Scholar
Lewis RA, Sumner AJ, Brown MJ, Asbury AK (1982) Multifocal demyelinating neuropathy with persistent conduction block. Neurology 32:958–964PubMedGoogle Scholar
Lievens I, Fournier E, Viala K, Maisonobe T, Bouche P, Léger JM (2009) Multifocal motor neuropathy: a retrospective study of sensory nerve conduction velocities in long-term follow-up of 21 patients. Rev Neurol 165:243–248CrossRefPubMedGoogle Scholar
Medical Research Council (1976) Aids to the examination to the peripheral nervous system. Her Majesty’s Stationary Office 1–2, LondonGoogle Scholar
Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G (1993) High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 43(3 Pt 1):537–544PubMedGoogle Scholar
Olney R, Lewis R, Putnam T, Campellone J (2003) American association of electrodiagnostic medicine. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27:117–121CrossRefPubMedGoogle Scholar
Parry GJ, Clarke S (1988) Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11:103–107CrossRefPubMedGoogle Scholar
Rajaballly YA, Chavada G (2009) Lewis–Sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve 39(2):206–220CrossRefGoogle Scholar
Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Polman CH, Wokke JH, Franssen H (2006) Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 77(6):743–747CrossRefPubMedGoogle Scholar
Verschueren A, Azulay JP, Attarian S, Boucraut J, Pellissier JF, Pouget J (2005) Lewis–Sumner syndrome and multifocal motor neuropathy. Muscle Nerve 31(1):88–94CrossRefPubMedGoogle Scholar
Viala K, Renié L, Maisonobe T et al (2004) Follow-up study and response to treatment in 23 patients with Lewis–Sumner syndrome. Brain 127(Pt 9):2010–2017CrossRefPubMedGoogle Scholar
Vucic S, Black K, Chong PS, Cros D (2007) Multifocal motor neuropathy with conduction block: distribution of demyelination and axonal degeneration. Clin Neurophysiol 118(1):124–130CrossRefPubMedGoogle Scholar